MAT2a and AHCY Inhibition Disrupts Antioxidant Metabolism and Reduces Glioblastoma Cell Survival

Emma C Rowland,Matthew D'Antuono,Anna Jermakowicz,Nagi G Ayad

DOI: https://doi.org/10.1101/2024.11.23.624981

2024-11-24

Abstract:Glioblastoma (GBM) is a highly aggressive primary malignant adult brain tumor that inevitably recurs with a fatal prognosis. This is due in part to metabolic reprogramming that allows tumors to evade treatment. We therefore must uncover the pathways mediating these adaptations to develop novel and effective treatments. We searched for genes that are essential in GBM cells as measured by a whole-genome pan-cancer CRISPR screen available from DepMap and identified the methionine metabolism genes MAT2A and AHCY. We conducted genetic knockdown, evaluated mitochondrial respiration, and performed targeted metabolomics to study the function of these genes in GBM. We demonstrate that MAT2A or AHCY knockdown induces oxidative stress, hinders cellular respiration, and reduces the survival of GBM cells. Furthermore, selective MAT2a or AHCY inhibition reduces GBM cell viability, impairs oxidative metabolism, and changes the metabolic profile of these cells towards oxidative stress and cell death. Mechanistically, MAT2a or AHCY regulates spare respiratory capacity, the redox buffer cystathionine, lipid and amino acid metabolism, and prevents DNA damage in GBM cells. Our results point to the methionine metabolic pathway as a novel vulnerability point in GBM.

Biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how the metabolic reprogramming of glioblastoma (GBM) leads to tumor resistance to treatment, and explores whether reducing the viability of GBM cells by inhibiting two key enzymes in the methionine metabolic pathway, MAT2a and AHCY, can provide potential targets for the development of new treatment methods. Specifically, through genome - wide pan - cancer CRISPR screening, the authors found that MAT2A and AHCY, two genes involved in methionine metabolism, play important roles in GBM cells. They explored the functions of these two genes in GBM through gene knockdown experiments, evaluation of mitochondrial respiratory function, and targeted metabolomics studies. The research results show that knockdown of MAT2A or AHCY can induce oxidative stress, impede cell respiration, and reduce the survival rate of GBM cells. In addition, selective inhibition of MAT2a or AHCY not only reduces the viability of GBM cells but also impairs oxidative metabolism, changes the metabolic profile of these cells, making them tend towards oxidative stress and cell death. Mechanistically, MAT2a or AHCY regulates mitochondrial spare respiratory capacity, the antioxidant buffer cystathionine, lipid and amino acid metabolism, and prevents DNA damage in GBM cells. Therefore, this study indicates that the methionine metabolic pathway may be a new vulnerability of GBM, and interventions targeting this pathway may help reduce tumor growth and improve patient survival rates. In short, this paper aims to reveal the role of methionine metabolism in maintaining the antioxidant capacity of GBM cells and promoting tumor cell survival, and proposes a new strategy of targeting this metabolic pathway to overcome the treatment challenges of GBM.

MAT2a and AHCY Inhibition Disrupts Antioxidant Metabolism and Reduces Glioblastoma Cell Survival

Metabolic Reprogramming in Glioblastoma Multiforme: A Review of Pathways and Therapeutic Targets

Tmet-24. Multi-Omic Characterization Of The Temporal Metabolic Adaptations Underpinning Therapy Resistance And Tumor Recurrence In Glioblastoma

Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells

ID2 promotes survival of glioblastoma cells during metabolic stress by regulating mitochondrial function

Reciprocal links between methionine metabolism, DNA repair and therapy resistance in glioblastoma

Targeting Microglial Metabolic Rewiring Synergizes with Immune Checkpoint Blockade Therapy for Glioblastoma

Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?

Genome-Scale Metabolic Modeling of Glioblastoma Reveals Promising Targets for Drug Development

Tmet-19. Rewiring Of Cortical Glucose Metabolism Fuels Human Brain Cancer Growth

Inhibiting Adenine Synthesis Attenuates Glioblastoma Cell Stemness and Temozolomide Resistance

Immu-58. Bcat1 Targeted Metabolic Reprogramming Plays Critical Roles In Modulating Myeloid Derived Suppressor Cell Function In Glioblastoma

Targeting BCAT1 Combined with α-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma

SMYD2 induced PGC1α methylation promotes stemness maintenance of glioblastoma stem cells

Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy

Metabolic Alterations in Highly Tumorigenic Glioblastoma Cells: PREFERENCE FOR HYPOXIA AND HIGH DEPENDENCY ON GLYCOLYSIS

Autophagy Mediates Glucose Starvation-Induced Glioblastoma Cell Quiescence and Chemoresistance Through Coordinating Cell Metabolism, Cell Cycle, and Survival

Purine Synthesis Inhibitor L-Alanosine Impairs Mitochondrial Function and Stemness of Brain Tumor Initiating Cells

Identification of Compounds That Decrease Glioblastoma Growth and Glucose Uptake in Vitro

Metabolic remodeling of pyrimidine synthesis pathway and serine synthesis pathway in human glioblastoma

A covalent creatine kinase inhibitor ablates glioblastoma migration and sensitizes tumors to oxidative stress